Insurer ownership of pharmacy benefit managers doesn’t appear to increase the cost of drugs in Medicare, though the jury’s still out, according to a new report from the HHS’ Office of the Inspector General. Government investigators analyzed 60 commonly used and high-cost drugs, and found the overall difference in their prices was negligible — less […]
You are unauthorized to view this page. Username Password Remember Me Forgot Password
A bipartisan group of lawmakers in both chambers of Congress has reintroduced a bill aimed at barring companies from owning both a pharmacy benefit manager and retail pharmacies. The bill, called the Patients Before Monopolies (PBM) Act, would force conglomerates that include a PBM to divest pharmacies that they own. The legislation has existed in
Bipartisan Lawmakers Reintroduce Bill Barring PBMs from Owning Pharmacies Read More »
You are unauthorized to view this page.
Bipartisan Lawmakers Reintroduce Bill Barring PBMs from Owning Pharmacies Read More »
The Pharmacy Benefit Manager (PBM) market is at a tipping point. Long-standing structural issues are now translating into real dissatisfaction, sharper scrutiny, and market share shifts away from traditional models. Several trends are driving this shift at once: rapidly rising pharmacy spend, growing fiduciary and regulatory pressure, and increasing demand from plan sponsors for better
Beyond the Middleman: The PBM Market at an Inflection Point Read More »
You are unauthorized to view this page.
Beyond the Middleman: The PBM Market at an Inflection Point Read More »
State efforts to regulate pharmacy benefit managers are colliding with federal law, reviving a power struggle over who can police the companies that manage drug benefits for most Americans. The states are trying to rein in the middlemen that negotiate drug prices and pay pharmacies, but they’re running into a federal law that has the
States’ Efforts to Rein in PBMs Hit a Legal Roadblock Read More »
You are unauthorized to view this page.
States’ Efforts to Rein in PBMs Hit a Legal Roadblock Read More »
It’s time for Drug Channels Institute’s (DCI) annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S. drug channels. These organizations continue to exert greater control over patient access, sites of care/dispensing, and pricing, although some have started to unwind their vertical integration strategies. Scrutiny of these companies’ actions continues
